Share Price and Basic Stock Data
Last Updated: January 17, 2026, 7:09 am
| PEG Ratio | 0.28 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ind-Swift Laboratories Ltd operates within the pharmaceuticals sector, where it reported a price of ₹101 and a market capitalization of ₹813 Cr. The company’s revenue from operations showed a fluctuating trend, starting with ₹1,039 Cr in FY 2022 and rising to ₹1,207 Cr in FY 2023. However, projections indicate a decline to ₹562 Cr for FY 2025, with trailing twelve-month revenues standing at ₹568 Cr. Quarterly sales also experienced variability, with a peak of ₹310.34 Cr in June 2023, but dipping to ₹289.71 Cr by September 2023. The decline in revenue is concerning, especially given the industry standard for pharmaceutical companies, which typically maintain steady growth due to continuous demand. The company’s operating profit margin (OPM) fluctuated significantly, recorded at 0.96% in the most recent period, reflecting challenges in maintaining profitability amidst these revenue fluctuations. This illustrates a critical area of focus for the company as it navigates the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Ind-Swift Laboratories’ profitability metrics highlight areas of both strength and concern. The net profit for FY 2023 was ₹48 Cr, with a notable increase to ₹539 Cr in FY 2024, before declining to ₹250 Cr for FY 2025. The earnings per share (EPS) reflected this trend, recorded at ₹8.06 in FY 2023, rising sharply to ₹91.18 in FY 2024 before falling to ₹41.32 in FY 2025. However, the company’s operating profit margin (OPM) and net profit margin faced challenges, standing at 0.96% and 44.60% respectively for FY 2025, the latter indicating a strong performance relative to typical sector margins. Additionally, the interest coverage ratio (ICR) was reported at 21.24x, suggesting that the company manages its debt obligations effectively, although the declining profit figures raise questions about sustained operational efficiency. The cash conversion cycle (CCC) stood at 112 days, indicating potential inefficiencies in working capital management, which could adversely affect liquidity.
Balance Sheet Strength and Financial Ratios
Ind-Swift Laboratories’ balance sheet shows a significant improvement in financial health, with total assets reported at ₹1,438 Cr and total liabilities at ₹1,460 Cr for FY 2025. The company’s reserves reached ₹1,226 Cr, showcasing a robust equity base bolstered by retained earnings. Borrowings were significantly reduced to ₹22 Cr, reflecting a strategic de-leveraging that enhances financial stability. The debt-to-equity ratio stood at 0.02, indicating minimal reliance on debt financing, which is favorable compared to industry norms. Key financial ratios also indicate healthy liquidity, with a current ratio of 3.92 and a quick ratio of 3.41, both above the typical threshold of 1.5 for healthy liquidity. However, the decline in return on equity (ROE) to 21.32% and return on capital employed (ROCE) to 3.08% raises concerns about the effective utilization of capital, particularly as the company transitions through fluctuating profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ind-Swift Laboratories reveals a diverse ownership structure, with promoters holding 39.49% as of September 2025. Foreign institutional investors (FIIs) have increased their stake significantly to 14.80%, indicating growing investor confidence in the company’s potential, particularly given the rising interest from FIIs over the past year. Domestic institutional investors (DIIs) have a minor presence at 0.68%, while public shareholding stands at 45.02%. The increase in the number of shareholders from 24,456 in December 2022 to 43,780 in September 2025 suggests a growing interest in the stock, reflecting positive sentiment among retail investors. However, the consistent decline in promoter holding from 42.01% in December 2022 to the current level raises questions about long-term commitment, which could impact investor sentiment if not addressed. This dynamic illustrates a critical balance between institutional support and retail investor interest.
Outlook, Risks, and Final Insight
Ind-Swift Laboratories faces a mixed outlook characterized by both opportunities and risks. The company’s significant reduction in debt and strong liquidity position presents a solid foundation for future growth, particularly if it can stabilize and grow its revenues. However, the recent decline in sales and profitability metrics poses a risk that could undermine investor confidence. Additionally, the pharmaceutical industry’s competitive nature necessitates continuous innovation and efficiency improvements to sustain market position. A critical area of focus should be improving operational efficiency, as evidenced by the cash conversion cycle and fluctuating profit margins. If the company can leverage its strong balance sheet to invest in growth initiatives, it may well navigate these challenges successfully. Conversely, failure to address declining revenue trends and maintain operational efficiency could lead to increased volatility in stock performance, complicating investor sentiment and long-term growth potential.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,986.51 Cr | 1,115.90 | 52.25 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 310.21 | 312.69 | 304.25 | 310.34 | 289.71 | 287.51 | 528.57 | 33.17 | 11.96 | 124.66 | 138.24 | 152.73 | 152.64 |
| Expenses | 251.45 | 258.93 | 240.58 | 250.05 | 224.02 | 235.82 | 437.36 | 42.91 | 23.76 | 131.31 | 147.44 | 149.13 | 151.17 |
| Operating Profit | 58.76 | 53.76 | 63.67 | 60.29 | 65.69 | 51.69 | 91.21 | -9.74 | -11.80 | -6.65 | -9.20 | 3.60 | 1.47 |
| OPM % | 18.94% | 17.19% | 20.93% | 19.43% | 22.67% | 17.98% | 17.26% | -29.36% | -98.66% | -5.33% | -6.66% | 2.36% | 0.96% |
| Other Income | 7.54 | 8.36 | -16.44 | 5.61 | 7.40 | 7.11 | 458.23 | 11.14 | 13.01 | 15.91 | 220.34 | 14.58 | 17.86 |
| Interest | 23.98 | 22.38 | 21.82 | 20.38 | 21.14 | 21.05 | 2.96 | 0.17 | 0.41 | 10.03 | -26.76 | 1.15 | 2.01 |
| Depreciation | 16.41 | 15.39 | 9.29 | 13.89 | 13.19 | 13.56 | 19.55 | 0.25 | 0.22 | 5.81 | 7.44 | 6.68 | 6.98 |
| Profit before tax | 25.91 | 24.35 | 16.12 | 31.63 | 38.76 | 24.19 | 526.93 | 0.98 | 0.58 | -6.58 | 230.46 | 10.35 | 10.34 |
| Tax % | 2.16% | -13.43% | 255.40% | 45.02% | 17.88% | 19.31% | 6.29% | -3.06% | 31.03% | -16.41% | 3.55% | 16.52% | 22.24% |
| Net Profit | 25.34 | 27.50 | -25.12 | 17.24 | 31.66 | 19.42 | 493.68 | 0.94 | 0.41 | -5.49 | 222.27 | 8.77 | 7.99 |
| EPS in Rs | 4.29 | 4.65 | -4.25 | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 | 0.98 |
Last Updated: January 1, 2026, 7:16 am
Below is a detailed analysis of the quarterly data for Ind-Swift Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 152.64 Cr.. The value appears to be declining and may need further review. It has decreased from 152.73 Cr. (Jun 2025) to 152.64 Cr., marking a decrease of 0.09 Cr..
- For Expenses, as of Sep 2025, the value is 151.17 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 149.13 Cr. (Jun 2025) to 151.17 Cr., marking an increase of 2.04 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.47 Cr.. The value appears to be declining and may need further review. It has decreased from 3.60 Cr. (Jun 2025) to 1.47 Cr., marking a decrease of 2.13 Cr..
- For OPM %, as of Sep 2025, the value is 0.96%. The value appears to be declining and may need further review. It has decreased from 2.36% (Jun 2025) to 0.96%, marking a decrease of 1.40%.
- For Other Income, as of Sep 2025, the value is 17.86 Cr.. The value appears strong and on an upward trend. It has increased from 14.58 Cr. (Jun 2025) to 17.86 Cr., marking an increase of 3.28 Cr..
- For Interest, as of Sep 2025, the value is 2.01 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.15 Cr. (Jun 2025) to 2.01 Cr., marking an increase of 0.86 Cr..
- For Depreciation, as of Sep 2025, the value is 6.98 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.68 Cr. (Jun 2025) to 6.98 Cr., marking an increase of 0.30 Cr..
- For Profit before tax, as of Sep 2025, the value is 10.34 Cr.. The value appears to be declining and may need further review. It has decreased from 10.35 Cr. (Jun 2025) to 10.34 Cr., marking a decrease of 0.01 Cr..
- For Tax %, as of Sep 2025, the value is 22.24%. The value appears to be increasing, which may not be favorable. It has increased from 16.52% (Jun 2025) to 22.24%, marking an increase of 5.72%.
- For Net Profit, as of Sep 2025, the value is 7.99 Cr.. The value appears to be declining and may need further review. It has decreased from 8.77 Cr. (Jun 2025) to 7.99 Cr., marking a decrease of 0.78 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.98. The value appears to be declining and may need further review. It has decreased from 1.45 (Jun 2025) to 0.98, marking a decrease of 0.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 965 | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,709 | 562 | 568 |
| Expenses | 906 | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | 1,403 | 581 | 579 |
| Operating Profit | 59 | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 306 | -19 | -11 |
| OPM % | 6% | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 18% | -3% | -2% |
| Other Income | -19 | -31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | 476 | 305 | 269 |
| Interest | 117 | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 104 | 3 | -14 |
| Depreciation | 66 | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 80 | 24 | 27 |
| Profit before tax | -142 | -143 | -83 | -55 | 36 | 50 | -20 | 18 | 13 | 87 | 598 | 258 | 245 |
| Tax % | -14% | -17% | -29% | -29% | 39% | 42% | 7% | 117% | 117% | 45% | 10% | 3% | |
| Net Profit | -122 | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 539 | 250 | 234 |
| EPS in Rs | -29.79 | -29.14 | -14.33 | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 | 91.18 | 41.32 | 38.17 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 2.46% | 50.42% | 33.90% | 156.41% | 31.82% | -172.41% | 85.71% | 33.33% | 2500.00% | 1022.92% | -53.62% |
| Change in YoY Net Profit Growth (%) | 0.00% | 47.96% | -16.52% | 122.51% | -124.59% | -204.23% | 258.13% | -52.38% | 2466.67% | -1477.08% | -1076.53% |
Ind-Swift Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -6% |
| 3 Years: | -19% |
| TTM: | -62% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 205% |
| TTM: | -88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 24% |
| 3 Years: | 20% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:51 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 42 | 42 | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 67 | 69 | 82 |
| Reserves | 684 | 553 | 476 | 486 | 507 | 540 | 581 | 544 | 541 | 622 | 745 | 1,104 | 1,226 |
| Borrowings | 1,355 | 1,413 | 1,457 | 1,242 | 1,083 | 1,148 | 1,031 | 1,005 | 953 | 862 | 217 | 41 | 22 |
| Other Liabilities | 258 | 236 | 240 | 364 | 387 | 188 | 198 | 210 | 247 | 280 | 432 | 224 | 215 |
| Total Liabilities | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 | 1,544 |
| Fixed Assets | 1,174 | 1,117 | 1,099 | 1,042 | 934 | 914 | 843 | 753 | 630 | 587 | 192 | 273 | 285 |
| CWIP | 78 | 113 | 78 | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 51 | 0 | 0 |
| Investments | 17 | 18 | 18 | 18 | 18 | 19 | 17 | 36 | 29 | 30 | 112 | 213 | 312 |
| Other Assets | 1,070 | 997 | 1,020 | 1,007 | 1,002 | 972 | 998 | 1,011 | 1,131 | 1,199 | 1,106 | 952 | 947 |
| Total Assets | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 | 1,544 |
Below is a detailed analysis of the balance sheet data for Ind-Swift Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 82.00 Cr.. The value appears strong and on an upward trend. It has increased from 69.00 Cr. (Mar 2025) to 82.00 Cr., marking an increase of 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,226.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,104.00 Cr. (Mar 2025) to 1,226.00 Cr., marking an increase of 122.00 Cr..
- For Borrowings, as of Sep 2025, the value is 22.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 41.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 19.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 215.00 Cr.. The value appears to be improving (decreasing). It has decreased from 224.00 Cr. (Mar 2025) to 215.00 Cr., marking a decrease of 9.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,544.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,438.00 Cr. (Mar 2025) to 1,544.00 Cr., marking an increase of 106.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 285.00 Cr.. The value appears strong and on an upward trend. It has increased from 273.00 Cr. (Mar 2025) to 285.00 Cr., marking an increase of 12.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 312.00 Cr.. The value appears strong and on an upward trend. It has increased from 213.00 Cr. (Mar 2025) to 312.00 Cr., marking an increase of 99.00 Cr..
- For Other Assets, as of Sep 2025, the value is 947.00 Cr.. The value appears to be declining and may need further review. It has decreased from 952.00 Cr. (Mar 2025) to 947.00 Cr., marking a decrease of 5.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,544.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,438.00 Cr. (Mar 2025) to 1,544.00 Cr., marking an increase of 106.00 Cr..
Notably, the Reserves (1,226.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 58.00 | 88.00 | 106.00 | 105.00 | 133.00 | 125.00 | 143.00 | 182.00 | -751.00 | -633.00 | 89.00 | -60.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 168 | 215 | 208 | 182 | 194 | 169 | 186 | 177 | 160 | 153 | 48 | 107 |
| Inventory Days | 182 | 312 | 368 | 305 | 291 | 284 | 315 | 301 | 288 | 242 | 6 | 145 |
| Days Payable | 103 | 120 | 137 | 91 | 118 | 114 | 124 | 111 | 118 | 113 | 52 | 140 |
| Cash Conversion Cycle | 247 | 407 | 439 | 396 | 367 | 339 | 377 | 367 | 330 | 282 | 2 | 112 |
| Working Capital Days | 129 | 141 | -26 | -97 | -49 | 217 | 248 | 253 | 253 | 234 | 2 | 141 |
| ROCE % | 0% | 1% | 2% | 2% | 4% | 4% | 5% | 7% | 7% | 13% | 20% | 3% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 37.25 | 71.24 | 8.10 | -0.36 | -0.53 |
| Diluted EPS (Rs.) | 35.21 | 71.24 | 8.10 | -0.36 | -0.53 |
| Cash EPS (Rs.) | 40.00 | 80.35 | 17.59 | 21.55 | 14.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 170.88 | 157.64 | 83.36 | 67.61 | 65.66 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 170.88 | 157.64 | 114.02 | 100.47 | 100.90 |
| Revenue From Operations / Share (Rs.) | 81.71 | 216.78 | 201.87 | 173.68 | 149.04 |
| PBDIT / Share (Rs.) | 9.02 | 50.70 | 43.92 | 39.98 | 34.36 |
| PBIT / Share (Rs.) | 5.46 | 41.68 | 34.33 | 18.07 | 19.77 |
| PBT / Share (Rs.) | 37.50 | 98.46 | 14.47 | 2.10 | 3.01 |
| Net Profit / Share (Rs.) | 36.44 | 71.33 | 8.00 | -0.35 | -0.52 |
| NP After MI And SOA / Share (Rs.) | 36.44 | 71.24 | 7.96 | -0.35 | -0.52 |
| PBDIT Margin (%) | 11.03 | 23.38 | 21.75 | 23.01 | 23.05 |
| PBIT Margin (%) | 6.67 | 19.22 | 17.00 | 10.40 | 13.26 |
| PBT Margin (%) | 45.89 | 45.41 | 7.16 | 1.20 | 2.02 |
| Net Profit Margin (%) | 44.60 | 32.90 | 3.96 | -0.20 | -0.35 |
| NP After MI And SOA Margin (%) | 44.59 | 32.86 | 3.94 | -0.20 | -0.35 |
| Return on Networth / Equity (%) | 21.32 | 45.19 | 9.54 | -0.53 | -0.80 |
| Return on Capital Employeed (%) | 3.08 | 26.09 | 14.13 | 7.36 | 7.86 |
| Return On Assets (%) | 17.41 | 36.13 | 2.60 | -0.11 | -0.17 |
| Long Term Debt / Equity (X) | 0.01 | 0.01 | 1.51 | 2.10 | 2.25 |
| Total Debt / Equity (X) | 0.02 | 0.01 | 1.73 | 2.35 | 2.56 |
| Asset Turnover Ratio (%) | 0.43 | 0.85 | 0.66 | 0.54 | 0.46 |
| Current Ratio (X) | 3.92 | 2.99 | 3.14 | 3.22 | 3.00 |
| Quick Ratio (X) | 3.41 | 2.94 | 1.96 | 1.94 | 1.81 |
| Inventory Turnover Ratio (X) | 9.01 | 5.70 | 1.52 | 1.33 | 1.23 |
| Interest Coverage Ratio (X) | 21.24 | 5.86 | 2.85 | 2.50 | 2.05 |
| Interest Coverage Ratio (Post Tax) (X) | 10.36 | 1.68 | 1.81 | 0.97 | 0.96 |
| Enterprise Value (Cr.) | 189.85 | 165.50 | 1173.71 | 1328.01 | 1424.06 |
| EV / Net Operating Revenue (X) | 0.33 | 0.12 | 0.97 | 1.28 | 1.60 |
| EV / EBITDA (X) | 3.06 | 0.55 | 4.47 | 5.55 | 6.93 |
| MarketCap / Net Operating Revenue (X) | 1.03 | 0.45 | 0.27 | 0.38 | 0.48 |
| Price / BV (X) | 0.49 | 0.62 | 0.66 | 0.98 | 1.10 |
| Price / Net Operating Revenue (X) | 1.03 | 0.45 | 0.27 | 0.38 | 0.48 |
| EarningsYield | 0.43 | 0.72 | 0.14 | -0.01 | -0.01 |
After reviewing the key financial ratios for Ind-Swift Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.25. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 37.25, marking a decrease of 33.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 35.21. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 35.21, marking a decrease of 36.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 40.00. This value is within the healthy range. It has decreased from 80.35 (Mar 24) to 40.00, marking a decrease of 40.35.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 170.88. It has increased from 157.64 (Mar 24) to 170.88, marking an increase of 13.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 170.88. It has increased from 157.64 (Mar 24) to 170.88, marking an increase of 13.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 81.71. It has decreased from 216.78 (Mar 24) to 81.71, marking a decrease of 135.07.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 9.02. This value is within the healthy range. It has decreased from 50.70 (Mar 24) to 9.02, marking a decrease of 41.68.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.46. This value is within the healthy range. It has decreased from 41.68 (Mar 24) to 5.46, marking a decrease of 36.22.
- For PBT / Share (Rs.), as of Mar 25, the value is 37.50. This value is within the healthy range. It has decreased from 98.46 (Mar 24) to 37.50, marking a decrease of 60.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 36.44. This value is within the healthy range. It has decreased from 71.33 (Mar 24) to 36.44, marking a decrease of 34.89.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 36.44. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 36.44, marking a decrease of 34.80.
- For PBDIT Margin (%), as of Mar 25, the value is 11.03. This value is within the healthy range. It has decreased from 23.38 (Mar 24) to 11.03, marking a decrease of 12.35.
- For PBIT Margin (%), as of Mar 25, the value is 6.67. This value is below the healthy minimum of 10. It has decreased from 19.22 (Mar 24) to 6.67, marking a decrease of 12.55.
- For PBT Margin (%), as of Mar 25, the value is 45.89. This value is within the healthy range. It has increased from 45.41 (Mar 24) to 45.89, marking an increase of 0.48.
- For Net Profit Margin (%), as of Mar 25, the value is 44.60. This value exceeds the healthy maximum of 10. It has increased from 32.90 (Mar 24) to 44.60, marking an increase of 11.70.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 44.59. This value exceeds the healthy maximum of 20. It has increased from 32.86 (Mar 24) to 44.59, marking an increase of 11.73.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.32. This value is within the healthy range. It has decreased from 45.19 (Mar 24) to 21.32, marking a decrease of 23.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.08. This value is below the healthy minimum of 10. It has decreased from 26.09 (Mar 24) to 3.08, marking a decrease of 23.01.
- For Return On Assets (%), as of Mar 25, the value is 17.41. This value is within the healthy range. It has decreased from 36.13 (Mar 24) to 17.41, marking a decrease of 18.72.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.43. It has decreased from 0.85 (Mar 24) to 0.43, marking a decrease of 0.42.
- For Current Ratio (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has increased from 2.99 (Mar 24) to 3.92, marking an increase of 0.93.
- For Quick Ratio (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 2. It has increased from 2.94 (Mar 24) to 3.41, marking an increase of 0.47.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.01. This value exceeds the healthy maximum of 8. It has increased from 5.70 (Mar 24) to 9.01, marking an increase of 3.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 21.24. This value is within the healthy range. It has increased from 5.86 (Mar 24) to 21.24, marking an increase of 15.38.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 10.36. This value is within the healthy range. It has increased from 1.68 (Mar 24) to 10.36, marking an increase of 8.68.
- For Enterprise Value (Cr.), as of Mar 25, the value is 189.85. It has increased from 165.50 (Mar 24) to 189.85, marking an increase of 24.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 1. It has increased from 0.12 (Mar 24) to 0.33, marking an increase of 0.21.
- For EV / EBITDA (X), as of Mar 25, the value is 3.06. This value is below the healthy minimum of 5. It has increased from 0.55 (Mar 24) to 3.06, marking an increase of 2.51.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 1.03, marking an increase of 0.58.
- For Price / BV (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.62 (Mar 24) to 0.49, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 1.03, marking an increase of 0.58.
- For EarningsYield, as of Mar 25, the value is 0.43. This value is below the healthy minimum of 5. It has decreased from 0.72 (Mar 24) to 0.43, marking a decrease of 0.29.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ind-Swift Laboratories Ltd:
- Net Profit Margin: 44.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.08% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 10.36
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.6 (Industry average Stock P/E: 52.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 44.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | SCO 850, Shivalik Enclave, Chandigarh Chandigarh 160101 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Navrattan Munjal | Chairman & Managing Director |
| Mr. Himanshu Jain | Joint Managing Director |
| Mr. Rishav Mehta | Executive Director |
| Mr. Sahil Munjal | Executive Director |
| Mr. Rajinder Kumar Gupta | Independent Director |
| Mr. Prabhat Khurana | Independent Director |
| Mr. Subodh Gupta | Independent Director |
| Ms. Neerja Chathley | Independent Woman Director |
FAQ
What is the intrinsic value of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd's intrinsic value (as of 17 January 2026) is ₹15.00 which is 86.49% lower the current market price of ₹111.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹905 Cr. market cap, FY2025-2026 high/low of ₹124/67.2, reserves of ₹1,226 Cr, and liabilities of ₹1,544 Cr.
What is the Market Cap of Ind-Swift Laboratories Ltd?
The Market Cap of Ind-Swift Laboratories Ltd is 905 Cr..
What is the current Stock Price of Ind-Swift Laboratories Ltd as on 17 January 2026?
The current stock price of Ind-Swift Laboratories Ltd as on 17 January 2026 is ₹111.
What is the High / Low of Ind-Swift Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ind-Swift Laboratories Ltd stocks is ₹124/67.2.
What is the Stock P/E of Ind-Swift Laboratories Ltd?
The Stock P/E of Ind-Swift Laboratories Ltd is 30.6.
What is the Book Value of Ind-Swift Laboratories Ltd?
The Book Value of Ind-Swift Laboratories Ltd is 160.
What is the Dividend Yield of Ind-Swift Laboratories Ltd?
The Dividend Yield of Ind-Swift Laboratories Ltd is 0.00 %.
What is the ROCE of Ind-Swift Laboratories Ltd?
The ROCE of Ind-Swift Laboratories Ltd is 0.78 %.
What is the ROE of Ind-Swift Laboratories Ltd?
The ROE of Ind-Swift Laboratories Ltd is 0.18 %.
What is the Face Value of Ind-Swift Laboratories Ltd?
The Face Value of Ind-Swift Laboratories Ltd is 10.0.